Anhui Deepblue Medical Technology Co., Ltd. (hereinafter referred to as "Deep Blue Medical") was established in February 2010. It is a new type of biopharmaceutical enterprise specializing in POCT, molecular precision diagnosis and treatment product services, and biological raw material research and development, production and sales. The scope includes the production and sales of Class I, Class II and Class III medical devices and in vitro diagnostic reagents.

As a pioneer in the IVD industry in Anhui Province, Deepblue Medical entered the international market in 2017. It has made outstanding contributions in rapid screening and testing of gynecological testing, infectious disease testing, cervical cancer, gastrointestinal tumor screening and other products, and has successively obtained TUV According to the EN ISO 13485:2016 quality system certification and CE product certification, the series of products are registered in many countries. Deepblue Medical's current main products include new coronavirus antigens, neutralizing antibody series test kits, infectious disease series test kits, gynecological test series kits, maternity test series kits, cervical cancer screening series kits, and digestive tract Tumor detection kits, medical ultrasonic coupling agent for cavity, medical ice cap, wound dressing and other products. In 2020, the series of new coronavirus detection products exported overseas have been highly praised by authoritative organizations such as Ospedale Universitario Sapienza di Italia, St Thomas’ Hospital, University of California, PHE Porton Down, etc. The product footprint has spread to nearly 100 countries and regions around the world.

Adhering to the business philosophy of "Integrity, Standardization, Innovation, and Development", the company has achieved a good reputation in the industry and has become a well-known enterprise in the IVD industry at home and abroad. Through the promotion of lean production, fine management, and meticulous service, Deepblue Medical promotes standard leadership, quality revolution, and brand building. It has an advantage in market segments with suitable varieties, excellent quality, and prestigious brands, and has the right to speak in industry standards and Brand influence. At the same time, the company introduces a new management model, through the share reform, encourages talent innovation, and jointly promotes the development of Deepblue.

Deepblue Medical adheres to an innovative development route. Its core products are protected by independent research and development. The company focuses on intellectual property cultivation, conducts industry-university-research cooperation, uses technological innovation to change the traditional industry single market development model, introduces big data platforms to the company, and develops e-commerce Sales, develop a brand-new business model, and belong to a typical Internet+ manufacturer. The company insists on innovation-driven, focusing on cultivating and expanding strategic emerging industries, transforming and upgrading traditional industries, carrying out technological innovation, management innovation and business model innovation, cultivating new growth points, and forming new competitive advantages. At present, Deep Blue Medical has applied for multi-directional trademark brands, mainly: DEEPBLUE, DeepBlue, Binggang, Bingzhining, DeepBlue Quick Reduction, and Xinxiaoan. Among them, "DEEPBLUE" has obtained the Madrid International Trademark Registration Certificate.